ALLMedicine™ Pleural Effusions Center

Jan 25th, 2023 - Pleural cytology is currently used to assess targetable mutations in patients with advanced lung adenocarcinoma. However, it is fraught with low diagnostic yield. Can pleural cell-free DNA (cfDNA) be used to assess targetable mutations in lung ade...

Dec 23rd, 2022 - Indwelling pleural catheters (IPCs) are a mainstay therapy for malignant pleural effusions (MPEs). Many patients treated with IPCs achieve pleurodesis. We aimed to identify the effect of systemic therapies for non-small cell lung cancer (NSCLC) on...

Dec 22nd, 2022 - Thoracentesis and thoracoscopy are used to diagnose malignant pleural effusions (MPE). Data on how sensitivity varies with tumour type is limited. Systematic review using PubMed was performed through August 2020 to determine the sensitivity of tho...

Dec 9th, 2022 - Malignant pleural effusions (MPEs) are common and associated with a poor prognosis. Yet, many patients face suboptimal management characterized by repeated, nondefinitive therapeutic procedures and potentially avoidable hospital admissions. We con...

Nov 8th, 2022 - Benign pleural effusions (BPEs) are more common than malignant effusions and their treatment involves treating the underlying disease process. However, in cases refractory to medical management, pleural interventions might be necessary. Use of ind...

Jul 29th, 2018 - Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE m...

Jan 17th, 2020 - Clinical pulmonary medicine Definitive pleural interventions in malignant pleural effusions Malignant pleural effusions (MPEs) contribute significantly to symptom burden, and an emphasis on patient-centered outcomes prioritizes palliation of sympt.